Nexus BioQuest Receives the King’s Award for Enterprise in International Trade 2026
Nexus BioQuest is delighted and honoured to have received The Kings Award for Enterprise in International Trade 2026, one of the UK’s most prestigious business accolades. The award was formally presented by the Vice Lord-Lieutenant of Somerset, Robbie Drewett, in recognition of the company’s outstanding achievements in international trade and its growing impact within the global life sciences sector.
The King’s Awards for Enterprise celebrate exceptional business success and recognise organisations that have demonstrated excellence, innovation and sustainable growth. Receiving this award is a significant milestone for Nexus BioQuest and reflects the dedication, expertise and ambition that have driven the company’s success since its founding.
Speaking during the presentation, the Vice Lord-Lieutenant highlighted the significance of the achievement:
“This is a very special achievement. The King’s Awards are among the highest honours that can be given to a business, and they are certainly not easy to win. So, receiving one is something about which everyone here should feel enormously proud.”
The award recognises Nexus BioQuest’s success in delivering high-quality immunology and translational research services to clients around the world. Through a commitment to scientific excellence, collaboration and customer partnership, the company has established itself as a trusted partner supporting drug discovery and development programmes across the biotechnology and pharmaceutical sectors.
Reflecting on the achievement, the leadership team shared their gratitude for everyone who has contributed to the company’s journey:
“This recognition belongs to an incredible team. Thank you to everyone at Nexus BioQuest for your commitment, ambition and professionalism. Thank you to our clients for partnering with us and backing our science. And thank you to our investors and board members for your belief, support and guidance as we grow.”
The team also reflected on the significance of receiving such a prestigious award at this stage of the company’s development:
“To have received this prestigious recognition so early in our journey is especially meaningful. It is a powerful validation of the work we do, the trust our clients place in us, and our belief that high-quality, science-led services from the UK can deliver a real global impact.”
Since its inception, Nexus BioQuest has remained focused on a clear vision: to build a trusted scientific partner delivering world-class immunology and translational research expertise.
“The King’s Award for Enterprise recognises the vision we set from the start: to build a trusted partner for immunology and translational research.”
Nexus BioQuest is immensely proud of this achievement and grateful to its employees, clients, investors and partners who have contributed to its success. As the company continues to grow its global presence, it remains committed to advancing scientific innovation and supporting the development of next-generation therapies that improve patient outcomes worldwide.
Read more in the King’s Awards Magazine feature: King’s Awards Magazine
